Hemophilia A
Conditions
Keywords
GreenGene™ F, Previously Treated Patients
Brief summary
This study primarily will address the safety and secondarily will assess efficacy of GreenGene™ F in subjects with severe hemophilia A previously treated ≥50 exposure days with a GreenGene™ F, and without presence inhibitor to FVIII (Factor VIII).
Interventions
BIOLOGICALGreenGene™ F
Prophylaxis safety and efficacy substudy: intra venous infusion, 30 ± 10 IU/kg infusions 3 times per week with dose escalation to 45 ± 10 IU/kg if appropriate, for 50 exposure days
Sponsors
Atlantic Research Group
Green Cross Corporation
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
1. Subjects must have participated in the GreenGene™ F\_P3, (with Eudra CT number 2012-001445-40) or a pediatric study with GreenGene™ F 2. Have ≥50 previous exposure days to GreenGene™ F, as documented in the subject's medical records. 3. Negative assays for FVIII inhibitor at inclusion (\<0.6BU Nijmegen assay), i.e. at the end of study GreenGene™ F\_P3 for patients entering into this extension study immediately after finishing the previous phase III study. 4. Normal liver and kidney function 5. Platelet count ≥ 100,000㎕ 6. Normal prothrombin time or International Normalized Ratio (INR) \< 1.5 7. Subjects receiving therapy for human immunodeficiency virus (HIV) or hepatitis must be on a stable treatment regimen 8. Subjects must be able to withhold FVIII infusions for approximately 72 h prior to each inhibitor assay 9. Absolute CD4 lymphocyte cell count ≥ 200㎕ 10. Signed the written informed consent form or informed consent was obtained from the subject's legal guardian 11. Females must not be lactating or pregnant at screening or Baseline (as documented by a negative beta-human chorionic gonadotropin \[β-hCG\] test with a minimum sensitivity of 25 IU/L or equivalent units of β-hCG). A test was obtained more than 72 hours before the first dose of study drug 12. All females will be considered to be of childbearing potential unless they are appropriate age group and without other known or suspected cause) or have been sterilized surgically (i.e. bilateral tubal ligation, total hysterectomy or bilateral oophorectomy, all with surgery at least one month before dosing) 13. Willing and able to comply with all aspects of the protocol
Exclusion criteria
1. Presence at Screening of FVIII inhibitor ≥ 0.6 BU as tested with the Nijmegen modification of the Bethesda assay. 2. Laboratory or clinical evidence of portal vein hypertension including, but not limited to, an INR \> 1.4, the presence of splenomegaly and/or spider angiomata of physical examination and/or a history of esophageal hemorrhage or documented esophageal varices 3. Uncontrolled hypertension (diastolic blood pressure \>100 mm Hg) 4. Hemoglobin \< 10 g/dL 5. Severe renal dysfunction (creatinine \> 2x upper limit of normal \[ULN\], total bilirubin \> 2x the ULN) 6. Liver disease (alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\] \> 3x the ULN) 7. History of diabetes or other metabolic disease 8. History of hypersensitivity or serious adverse reaction to recombinant or plasma-derived FVIII concentrates 9. History of pretreatment prior to the administration of FVIII products (e.g., antihistamines) 10. Regular use of antifibrinolytics or medications affecting platelet function 11. Hypersensitivity to hamster- or mouse derived proteins 12. Blood transfusions within 30 days of enrollment into the study 13. Current participation in another investigational drug or device study, or participated in a clinical study involving an investigational drug or device within 30 days of enrollment into the study 14. Unable or unwilling to cooperate with study procedures 15. Females who are pregnant (positive β-hCG test) or breastfeeding
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of subjects with development of inhibitors | every 3 months, up to 18 months | Development of neutralizing antibodies (inhibitors) will be followed during the regular visits, average of 3 months. |
Countries
United States
Contacts
Primary ContactChang Hee Lee, M.D.
Backup ContactKevin Wait
Outcome results
None listed